The HS3ST1 Knockout UM-UC-3 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the human UM-UC-3 urothelial carcinoma cell line, featuring targeted disruption of the HS3ST1 gene. This knockout model provides a genetically defined loss-of-function system for investigating heparan sulfate 3-O-sulfotransferase 1 function in a bladder cancer context. The polyclonal format avoids clonal selection-associated artifacts and maintains the heterogeneity typical of tumor cell populations, making it suitable for studying HS3ST1-dependent processes in a polygenic background. Researchers can utilize this product to dissect the contribution of HS3ST1 to heparan sulfate modification, coagulation modulation, and growth factor signaling without the confounding effects of single-cell clonal variation.
The parental UM-UC-3 cell line was established from a male patient with transitional cell carcinoma of the bladder and exhibits an epithelial morphology characteristic of the tissue of origin. Widely employed as an in vitro model for bladder transitional cell carcinoma, UM-UC-3 cells display aggressive growth properties and are permissive for tumor biology studies including invasion, migration, and drug response. The availability of a defined HS3ST1 knockout in this well-characterized background enables direct comparison between wild-type and HS3ST1-deficient cells, facilitating precise attribution of phenotypic changes to sulfotransferase activity.
The HS3ST1 enzyme catalyzes the transfer of sulfate to the 3-O position of N-sulfoglucosamine residues within heparan sulfate chains, a modification that generates high-affinity binding sites for antithrombin III and critically enhances its anticoagulant function. Beyond coagulation, 3-O-sulfated motifs also interact with growth factors such as FGF2 and VEGF, modulating their receptor binding and downstream signaling cascades. HS3ST1 expression is regulated by upstream inputs from FGF signaling, TGF-beta, and inflammatory cytokines (IL-1B and TNF), and the enzyme operates in concert with the EXT1/EXT2 copolymerase complex and the NDST1 N-deacetylase/N-sulfotransferase to determine the fine structure of heparan sulfate. Key downstream effects include antithrombin III activation, integrin-mediated adhesion modulation, and altered FGF2- and VEGF-driven signaling through the FGFR/MAPK/ERK pathway, positioning HS3ST1 at a regulatory node in both coagulation and growth factor biology.
In the context of urothelial carcinoma, dysregulation of HS3ST1 expression can perturb the balance between procoagulant and anticoagulant mechanisms and may influence tumor-stroma interactions through altered growth factor presentation. HS3ST1-modified heparan sulfate chains on syndecan-1 and other proteoglycans are thought to affect cell migration, invasion, and angiogenesis??processes central to metastatic progression. The UM-UC-3 knockout cells thus offer a relevant platform to dissect how loss of 3-O-sulfation impacts bladder cancer cell behavior under defined culture conditions or in co-culture models mimicking the tumor microenvironment. Such studies can clarify the contribution of HS3ST1 to thrombotic risk and aggressive phenotypes observed in bladder cancer patients.
This knockout product is well-suited for a range of advanced applications, including heparan sulfate structural analysis via LC-MS disaccharide profiling and functional anticoagulant activity assays to quantify antithrombin III potentiation. Gene expression validation by RT-qPCR and protein-level confirmation by western blotting or flow cytometry can complement migration assays and cell adhesion studies to link HS3ST1 loss to phenotypic outcomes. Co-immunoprecipitation experiments with antithrombin III or FGF2 enable investigation of altered ligand binding. Additionally, the cells serve as a screening tool for small-molecule sulfotransferase inhibitors. For detailed product specifications, lot-specific validation data, or technical support, please contact Ascent Research.
